Center-Authored Papers

Filters: Author is Hussain, Maha H A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Flaig TW, Plets M, Hussain MHA, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM.  2017.  Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.. JAMA oncology. Abstract
Sartor OA, Tangen CM, Hussain MHA, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford DE.  2008.  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).. Cancer. 112(11):2393-400. Abstract
I
Tangen CM, Hussain MHA, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford DE, Vogelzang NJ et al..  2012.  Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346).. The Journal of urology. 188(4):1164-9. Abstract
R
Flaig TW, Tangen CM, Hussain MHA, Stadler WM, Raghavan D, Crawford DE, Glodé ML.  2008.  Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(9):1532-6. Abstract
S
deVere White RW, Lara PN, Goldman B, Tangen CM, Smith DC, Wood DP, Hussain MHA, Crawford DE.  2009.  A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).. The Journal of urology. 181(6):2476-80;discussion2480-1. Abstract
V
Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS et al..  2017.  Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.. Clinical genitourinary cancer. Abstract